Kajodan (Potassium Iodide)

Potassium iodide supplies a large amount of stable iodide that quickly saturates the thyroid's sodium‑iodide symporter. This saturation blocks the gland from absorbing radioactive iodine isotopes, thereby reducing the radiation dose that would otherwise be incorporated into thyroid hormones.

The appropriate dose of Kajodan is determined by the prescribing healthcare professional based on the specific exposure scenario, age, weight, and medical condition of the patient. No fixed regimen is provided here; the prescriber sets the exact amount and timing.

Safety of potassium iodide during pregnancy or lactation should be evaluated by a qualified clinician. While short‑term use for emergency thyroid protection may be considered, the potential risks and benefits must be weighed individually, and medical advice is essential.

To order Kajodan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Kajodan is other stable iodine preparations such as saturated solution of potassium iodide (SSKI). Kajodan offers the same active ingredient in a convenient oral dosage, while alternative formulations may differ in concentration, tablet size, or liquid form. Clinical effectiveness is comparable when the correct dose is administered.

Kajodan should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Kajodan is taken orally, usually with a full glass of water. The tablet (or liquid, if supplied) should be swallowed whole and not chewed, unless the prescribing information states otherwise. Administration is typically performed as a single dose shortly before or after potential radioactive iodine exposure.

Serious risks include severe allergic reactions such as anaphylaxis, rare but significant thyroid dysfunction (both hypo‑ and hyperthyroidism), and iodide toxicity that can lead to pulmonary edema. Immediate medical attention is required if symptoms like difficulty breathing, rash, swelling, or abnormal thyroid signs develop.

Kajodan should be avoided in individuals with known hypersensitivity to potassium iodide or other iodine compounds, in patients with certain thyroid disorders where excess iodine could worsen the condition, and in those who are already receiving high‑dose iodine therapy unless specifically directed by a physician.